8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 25, 2026·SEC
Material company update
Nov 13, 2025·SEC
Precigen, Inc.(PGEN)Earnings, Financials & Key Ratios
PGEN•NASDAQ
Price updated Jun 19, 2026
AboutPrecigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.Show more
- Revenue$10M+146.7%
- EBITDA-$103M+20.8%
- Net Income-$251M-98.6%
- EPS (Diluted)-1.41-200.0%
- Gross Margin37.05%+525.2%
- EBITDA Margin-1067.75%+67.9%
- Operating Margin-1100.78%+68.0%
- Net Margin-2588.21%+19.5%
- ROE-843.57%-424.6%
PGEN Key Insights
Precigen, Inc. (PGEN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 82 (top 18%)
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Sales declining 21.3% over 5 years
- ✗Shares diluted 13.8% in last year
- ✗Expensive at 70.2x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PGEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PGEN Price & Volume
Precigen, Inc. (PGEN) stock price & volume — 10-year historical chart
Loading chart...
PGEN Growth Metrics
Precigen, Inc. (PGEN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-25.07%
5 Years-21.26%
3 Years-28.87%
TTM652.08%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-30.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-127.11%
Return on Capital
10 Years-48.2%
5 Years-66.73%
3 Years-90.05%
Last Year-87.71%
PGEN Recent Earnings
Precigen, Inc. (PGEN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 3/12 qtrs (27%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.02+33.3%
$0.03
Rev
$23M+11.8%
$21M
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$0.01+90.0%
$0.10
Rev
$5M-45.6%
$8M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.11-37.5%
$0.08
Rev
$3M-64.7%
$8M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.11+21.4%
$0.14
Rev
$856,000-8.3%
$933,330
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.02vs $0.03+33.3% | $23Mvs $21M+11.8% |
| Q2 2026 | Mar 25, 2026 | $0.01vs $0.10+90.0% | $5Mvs $8M-45.6% |
| Q4 2025 | Nov 13, 2025 | $0.11vs $0.08-37.5% | $3Mvs $8M-64.7% |
| Q3 2025 | Aug 12, 2025 | $0.11vs $0.14+21.4% | $856,000vs $933,330-8.3% |
Based on last 12 quarters of dataView full earnings history →
PGEN Peer Comparison
Precigen, Inc. (PGEN) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 SNDX | 1.68B | 19.00 | -5.78 | 6.28% | -112.01% | -256.66% | 5.36 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 CRIS | 81.52M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 |
Compare PGEN vs Peers
Precigen, Inc. (PGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PGEN Income Statement
Precigen, Inc. (PGEN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 230.98M | 160.57M | 31.99M | 31.99M | 14.27M | 26.91M | 6.22M | 3.92M | 9.68M | 31.59M |
Revenue Growth % | 20.98% | -30.48% | -80.08% | 0% | -55.4% | 88.61% | -76.87% | -36.95% | 146.73% | 652.08% |
Cost of Goods Sold | 62.79M | 63.29M | 5.37M | 44.8M | 53.68M | 6.34M | 6.12M | 4.27M | 6.1M | 7.7M |
COGS % of Revenue | 27.18% | 39.41% | 16.8% | 140.04% | 376.24% | 23.56% | 98.3% | 108.71% | 62.95% | - |
Gross Profit | 168.19M▲ 0% | 97.29M▼ 42.2% | 26.62M▼ 72.6% | -12.81M▼ 148.1% | -39.41M▼ 207.7% | 20.57M▲ 152.2% | 106K▼ 99.5% | -342K▼ 422.6% | 3.59M▲ 1149.1% | 23.9M▲ 0% |
Gross Margin % | 72.82% | 60.59% | 83.2% | -40.04% | -276.24% | 76.44% | 1.7% | -8.71% | 37.05% | 75.63% |
Gross Profit Growth % | 30.09% | -42.16% | -72.64% | -148.13% | -207.66% | 152.19% | -99.48% | -422.64% | 1149.12% | - |
Operating Expenses | 289.31M | 542.39M | 112.94M | 73.51M | 52.54M | 96.3M | 99.86M | 134.69M | 110.19M | 117.8M |
OpEx % of Revenue | 125.25% | 337.78% | 353.01% | 229.77% | 368.24% | 357.86% | 1604.24% | 3431.52% | 1137.84% | - |
Selling, General & Admin | 146.1M | 137.81M | 72.69M | 0 | 0 | 48.01M | 40.41M | 41.29M | 70.13M | 62.69M |
SG&A % of Revenue | 63.25% | 85.82% | 227.23% | - | - | 178.4% | 649.24% | 1052.05% | 724.16% | - |
Research & Development | 143.21M | 404.59M | 39.43M | 39.43M | 47.93M | 47.17M | 48.61M | 53.07M | 40.06M | 35.54M |
R&D % of Revenue | 62% | 251.96% | 123.24% | 123.24% | 335.97% | 175.29% | 780.95% | 1352.1% | 413.67% | - |
Other Operating Expenses | 1.01M | 630K | 814K | 34.08M | 4.6M | 1.12M | 10.84M | 40.32M | 0 | 1000K |
Operating Income | -137.89M▲ 0% | -505.61M▼ 266.7% | -86.32M▲ 82.9% | -86.32M▲ 0.0% | -91.95M▼ 6.5% | -75.73M▲ 17.6% | -99.76M▼ 31.7% | -135.03M▼ 35.4% | -106.6M▲ 21.1% | -93.91M▲ 0% |
Operating Margin % | -59.7% | -314.88% | -269.81% | -269.81% | -644.48% | -281.42% | -1602.54% | -3440.23% | -1100.78% | -297.21% |
Operating Income Growth % | -10.17% | -266.68% | 82.93% | 0% | -6.52% | 17.64% | -31.74% | -35.36% | 21.05% | - |
EBITDA | -106.75M | -481.5M | -68.8M | -68.8M | -78.19M | -64.96M | -93.09M | -130.5M | -103.4M | -90.24M |
EBITDA Margin % | -46.21% | -299.86% | -215.06% | -215.06% | -548.03% | -241.41% | -1495.42% | -3324.92% | -1067.75% | -285.6% |
EBITDA Growth % | -6.11% | -351.08% | 85.71% | 0% | -13.64% | 16.92% | -43.3% | -40.19% | 20.77% | 30.4% |
D&A (Non-Cash Add-back) | 31.14M | 24.11M | 17.52M | 17.52M | 13.76M | 10.77M | 6.67M | 4.53M | 3.2M | 3.67M |
EBIT | -129.09M | -387.44M | -86.31M | -85.5M | -91.41M | -73.19M | -95.89M | -128.02M | -106.6M | -90M |
Net Interest Income | 18.85M | 10.54M | -17.2M | -15.95M | -18.58M | -6.64M | 2.77M | 1.41M | -652K | -3.79M |
Interest Income | 19.48M | 19.08M | 1.01M | 2.45M | 171K | 133K | 3.24M | 1.42M | 3.21M | 2.98M |
Interest Expense | 611K | 8.53M | 18.21M | 18.4M | 18.75M | 6.77M | 468K | 6K | 3.87M | 6.77M |
Other Income/Expense | 17.8M | -26.25M | -18.21M | -18.21M | -19.02M | -4.24M | 3.4M | 7M | -144.04M | -110.51M |
Pretax Income | -129.7M▲ 0% | -536.23M▼ 313.4% | -104.52M▲ 80.5% | -104.52M▲ 0.0% | -110.97M▼ 6.2% | -79.97M▲ 27.9% | -96.36M▼ 20.5% | -128.03M▼ 32.9% | -250.64M▼ 95.8% | -204.41M▲ 0% |
Pretax Margin % | -56.15% | -333.95% | -326.72% | -326.72% | -777.79% | -297.17% | -1547.98% | -3261.86% | -2588.18% | -646.99% |
Income Tax | -2.88M | -21.53M | -82K | -82K | -160K | -189K | -458K | -1.79M | 3K | 3K |
Effective Tax Rate % | 2.22% | 4.01% | 0.08% | 0.08% | 0.14% | 0.24% | 0.48% | 1.4% | -0% | -0% |
Net Income | -117.02M▲ 0% | -509.34M▼ 335.3% | -170.52M▲ 66.5% | -170.52M▲ 0.0% | -92.17M▲ 46.0% | 28.32M▲ 130.7% | -95.9M▼ 438.7% | -126.23M▼ 31.6% | -250.64M▼ 98.6% | -204.42M▲ 0% |
Net Margin % | -50.66% | -317.2% | -533.01% | -533.01% | -646.01% | 105.23% | -1540.63% | -3216.18% | -2588.21% | -646.99% |
Net Income Growth % | 37.29% | -335.26% | 66.52% | 0% | 45.95% | 130.72% | -438.68% | -31.63% | -98.55% | -30.49% |
Net Income (Continuing) | -126.82M | -380.49M | -104.44M | -104.44M | -110.81M | -79.78M | -95.9M | -126.23M | -250.64M | -204.42M |
Discontinued Operations | 0 | 0 | -66.08M | -66.08M | 18.64M | 108.09M | 0 | 0 | 0 | 0 |
Minority Interest | 12.91M | 15.87M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.98▲ 0% | -3.93▼ 301.0% | -1.35▲ 65.6% | -1.02▲ 24.4% | -0.47▲ 53.9% | -0.40▲ 14.9% | -0.39▲ 2.5% | -0.47▼ 20.5% | -1.41▼ 200.0% | -0.65▲ 0% |
EPS Growth % | 37.97% | -301.02% | 65.65% | 24.44% | 53.92% | 14.89% | 2.5% | -20.51% | -200% | -127.11% |
EPS (Basic) | -0.98 | -3.93 | -1.35 | -1.02 | -0.47 | -0.33 | -0.39 | -0.47 | -1.41 | - |
Diluted Shares Outstanding | 120M | 129.52M | 154.14M | 167.07M | 197.76M | 200.36M | 244.54M | 267.73M | 304.71M | 312.98M |
Basic Shares Outstanding | 120M | 129.52M | 154.14M | 167.07M | 197.76M | 200.36M | 244.54M | 267.73M | 304.71M | 312.98M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PGEN Balance Sheet
Precigen, Inc. (PGEN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 154.05M | 285.48M | 234.64M | 148.95M | 156.63M | 118.16M | 68.75M | 102.41M | 115.23M | 101.67M |
Cash & Short-Term Investments | 79.67M | 222.84M | 75.05M | 100.12M | 108.66M | 55.95M | 62.85M | 97.91M | 97.86M | 56.25M |
Cash Only | 68.11M | 102.77M | 65.79M | 51.79M | 36.42M | 4.86M | 7.58M | 29.52M | 30.23M | 7.48M |
Short-Term Investments | 11.56M | 120.07M | 9.26M | 48.33M | 72.24M | 51.09M | 55.28M | 68.39M | 67.62M | 48.77M |
Accounts Receivable | 39.84M | 26.57M | 26.22M | 20.43M | 1.98M | 13.8M | 1.57M | 1.16M | 4.36M | 26.7M |
Days Sales Outstanding | 62.96 | 60.38 | 299.17 | 233.05 | 50.66 | 187.24 | 92.35 | 108.15 | 164.41 | 94.55 |
Inventory | 20.49M | 21.45M | 16.1M | 11.36M | 326K | 287K | 0 | 0 | 9.58M | 14.72M |
Days Inventory Outstanding | 119.13 | 123.69 | 1.09K | 92.54 | 2.22 | 16.53 | - | - | 573.67 | 324.34 |
Other Current Assets | 6.99M | 16.14M | 111.44M | 9.85M | 38.92M | 48.12M | 4.33M | 3.34M | 3.43M | 4M |
Total Non-Current Assets | 692.8M | 430.69M | 221.12M | 165.64M | 203.23M | 97.82M | 82.29M | 42.85M | 41.39M | 36.95M |
Property, Plant & Equipment | 112.67M | 128.87M | 86.2M | 44.28M | 18.55M | 15.29M | 14.13M | 18.8M | 18.44M | 17.59M |
Fixed Asset Turnover | 2.05x | 1.25x | 0.37x | 0.72x | 0.77x | 1.76x | 0.44x | 0.21x | 0.53x | 1.68x |
Goodwill | 153.29M | 149.59M | 63.75M | 54.36M | 37.55M | 36.92M | 26.61M | 19.14M | 15.23M | 15.23M |
Intangible Assets | 232.88M | 129.29M | 68.35M | 65.4M | 52.29M | 44.45M | 40.7M | 4.46M | 3.18M | 2.86M |
Long-Term Investments | 189.91M | 20.85M | 1.46M | 0 | 48.56M | 399K | 0 | 0 | 2.51M | 5.51M |
Other Non-Current Assets | 4.05M | -6.33M | -13.88M | -8.12M | 46.27M | -8.42M | 846K | 459K | 908K | 782K |
Total Assets | 846.85M▲ 0% | 716.18M▼ 15.4% | 455.76M▼ 36.4% | 314.59M▼ 31.0% | 359.86M▲ 14.4% | 215.98M▼ 40.0% | 151.04M▼ 30.1% | 145.27M▼ 3.8% | 156.62M▲ 7.8% | 138.63M▲ 0% |
Asset Turnover | 0.27x | 0.22x | 0.07x | 0.10x | 0.04x | 0.12x | 0.04x | 0.03x | 0.06x | 0.22x |
Asset Growth % | -10.77% | -15.43% | -36.36% | -30.98% | 14.39% | -39.98% | -30.07% | -3.82% | 7.82% | 159.91% |
Total Current Liabilities | 80.17M | 61.56M | 122.91M | 42.13M | 34.65M | 78.64M | 22.98M | 21.52M | 37.31M | 21.1M |
Accounts Payable | 8.7M | 11.97M | 5.53M | 4.6M | 3.11M | 4.07M | 1.73M | 3.53M | 11.98M | 2.59M |
Days Payables Outstanding | 50.58 | 69.05 | 375.46 | 37.46 | 21.16 | 234.24 | 102.96 | 302.04 | 717.61 | 293.44 |
Short-Term Debt | 735K | 945K | 33.59M | 360K | 52K | 43.22M | 0 | 0 | 1.14M | 1.07M |
Deferred Revenue (Current) | 42.87M | 15.55M | 5.7M | 2.8M | 1.49M | 25K | 509K | 589K | 0 | 1.3M |
Other Current Liabilities | 21.08M | 27.34M | 62.21M | 22.14M | 20.71M | 23.75M | 8.25M | 8.42M | 24.18M | 12.48M |
Current Ratio | 1.92x | 4.64x | 1.91x | 3.54x | 4.52x | 1.50x | 2.99x | 4.76x | 3.09x | 4.82x |
Quick Ratio | 1.67x | 4.29x | 1.78x | 3.27x | 4.51x | 1.50x | 2.99x | 4.76x | 2.83x | 4.12x |
Cash Conversion Cycle | 131.51 | 115.02 | 1.02K | 288.14 | 31.71 | -30.47 | - | - | 20.47 | 125.45 |
Total Non-Current Liabilities | 220.13M | 275.89M | 261.14M | 205.29M | 217.86M | 11.07M | 9.56M | 85.23M | 98.4M | 97.29M |
Long-Term Debt | 7.54M | 211.22M | 186.32M | 171.52M | 179.88M | 0 | 0 | 0 | 0 | 93.52M |
Capital Lease Obligations | 0 | 0 | 10.12M | 7.74M | 8.75M | 6.99M | 5.89M | 4.55M | 3.98M | 16.05M |
Deferred Tax Liabilities | 15.62M | 7.21M | 2.83M | 2.9M | 2.54M | 2.26M | 1.85M | 0 | 1.12M | 1.12M |
Other Non-Current Liabilities | 3.45M | 64.68M | 13.73M | 100K | 3.67M | 0 | 0 | 78.75M | 93.31M | 106K |
Total Liabilities | 300.31M | 337.45M | 384.05M | 247.41M | 252.51M | 89.72M | 32.55M | 106.75M | 135.71M | 118.39M |
Total Debt | 8.27M | 212.26M | 232.67M | 182.28M | 190.07M | 51.42M | 7.1M | 5.5M | 5.12M | 98.25M |
Net Debt | -59.84M | 109.49M | 166.87M | 130.49M | 153.65M | 46.56M | -481K | -24.02M | -25.12M | 90.77M |
Debt / Equity | 0.02x | 0.56x | 3.24x | 2.71x | 1.77x | 0.41x | 0.06x | 0.14x | 0.24x | 4.86x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.09x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.01x |
Interest Coverage | -211.27x | -45.42x | -4.74x | -4.65x | -4.87x | -10.80x | -204.90x | -21337.00x | -27.57x | -13.29x |
Total Equity | 546.54M▲ 0% | 378.72M▼ 30.7% | 71.71M▼ 81.1% | 67.17M▼ 6.3% | 107.35M▲ 59.8% | 126.26M▲ 17.6% | 118.5M▼ 6.1% | 38.51M▼ 67.5% | 20.91M▼ 45.7% | 20.23M▲ 0% |
Equity Growth % | -3.99% | -30.71% | -81.06% | -6.33% | 59.81% | 17.62% | -6.15% | -67.5% | -45.7% | -11.37% |
Book Value per Share | 4.55 | 2.92 | 0.47 | 0.40 | 0.54 | 0.63 | 0.48 | 0.14 | 0.07 | 0.06 |
Total Shareholders' Equity | 533.63M | 362.86M | 71.71M | 67.17M | 107.35M | 126.26M | 118.5M | 38.51M | 20.91M | 20.23M |
Common Stock | 580.07M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -847.82M | -1.33B | -1.65B | -1.82B | -1.92B | -1.87B | -1.96B | -2.09B | -2.34B | -2.35B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -15.55M | -28.61M | -27.47M | 4M | 203K | -3.49M | -1.95M | 12K | 0 | -17K |
Minority Interest | 12.91M | 15.87M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PGEN Cash Flow Statement
Precigen, Inc. (PGEN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -104.14M | -124.24M | -77.02M | -77.02M | -55.77M | -65.05M | -66.93M | -68.17M | -87.83M | -115.33M |
Operating CF Margin % | -45.09% | -77.37% | -240.75% | -240.75% | -390.91% | -241.72% | -1075.18% | -1736.89% | -906.97% | - |
Operating CF Growth % | -86.05% | -19.3% | 38.01% | 0% | 27.59% | -16.63% | -2.9% | -1.86% | -28.84% | -363.07% |
Net Income | -126.82M | -514.71M | -170.52M | -170.52M | -92.17M | 28.32M | -95.9M | -126.23M | -250.64M | -204.42M |
Depreciation & Amortization | 31.14M | 33.11M | 17.52M | 17.52M | 13.76M | 10.77M | 6.67M | 4.53M | 3.2M | 3.67M |
Stock-Based Compensation | 52.69M | 46.99M | 18.37M | 18.37M | 13.9M | 10.21M | 9.89M | 9.47M | 10.87M | 11.2M |
Deferred Taxes | -2.53M | -21.28M | -156K | -156K | -167K | -150K | -479K | -1.79M | 0 | 0 |
Other Non-Cash Items | 15.95M | 351.63M | 78.42M | 78.42M | 9.7M | -78.48M | -4.17M | 41.34M | 142.12M | 110.32M |
Working Capital Changes | -74.58M | -19.98M | -20.65M | -20.65M | -804K | -35.7M | 17.07M | 4.52M | 6.62M | -36.1M |
Change in Receivables | 740K | -2.7M | 4.33M | 4.33M | -6.56M | -13.51M | 12.23M | 414K | -3.2M | -25.64M |
Change in Inventory | 663K | -478K | 2.51M | 2.51M | -1.9M | 2.34M | 0 | 0 | -9.21M | -11.14M |
Change in Payables | -3.4M | 4.68M | -1.1M | -1.1M | 420K | 379K | -2.42M | 1.55M | 8.77M | -628K |
Cash from Investing | 104.33M | -151.21M | 27.78M | 27.78M | -74.54M | 226.42M | -3.09M | -20.71M | -1.53M | 25.89M |
Capital Expenditures | -46.67M | -41.59M | -7.53M | -7.53M | -7.25M | -4.92M | -1.54M | -8.58M | -2M | -2.23M |
CapEx % of Revenue | 20.2% | 25.9% | 23.53% | 23.53% | 50.8% | 18.3% | 24.67% | 218.7% | 20.6% | 7.07% |
Acquisitions | -23.35M | -14.9M | -10.83M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 736K | 17.77M | 84.5M | 73.67M | 6.76M | 162.9M | 98K | 60K | 0 | 46.32M |
Cash from Financing | 4.28M | 309.8M | 32.7M | 32.7M | 121.19M | -155.29M | 29.59M | 110.58M | 90.05M | 90.84M |
Debt Issued (Net) | -781K | 219.47M | -2.41M | -2.41M | -466K | -155.29M | -43.22M | 0 | 92.82M | 92.82M |
Equity Issued (Net) | 13.69M | 87.99M | 35M | 35M | 121.05M | 0 | 72.81M | 110.24M | 310K | 770K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -8.62M | 2.34M | 117K | 117K | 608K | 1K | 0 | 346K | -3.08M | -2.75M |
Net Change in Cash | 5.5M▲ 0% | 34.64M▲ 529.3% | -16.18M▼ 146.7% | -16.18M▲ 0.0% | -8.91M▲ 45.0% | 5.25M▲ 159.0% | -40.75M▼ 875.7% | 21.67M▲ 153.2% | 717K▼ 96.7% | 1.42M▲ 0% |
Free Cash Flow | -150.81M▲ 0% | -165.83M▼ 10.0% | -84.55M▲ 49.0% | -84.55M▲ 0.0% | -63.02M▲ 25.5% | -69.97M▼ 11.0% | -68.47M▲ 2.1% | -76.76M▼ 12.1% | -89.83M▼ 17.0% | -117.57M▲ 0% |
FCF Margin % | -65.29% | -103.27% | -264.28% | -264.28% | -441.7% | -260.02% | -1099.86% | -1955.59% | -927.57% | -372.11% |
FCF Growth % | -72.14% | -9.96% | 49.01% | 0% | 25.46% | -11.03% | 2.15% | -12.11% | -17.03% | -56.21% |
FCF per Share | -1.26 | -1.28 | -0.55 | -0.51 | -0.32 | -0.35 | -0.28 | -0.29 | -0.29 | -0.38 |
FCF Conversion (FCF/Net Income) | 0.89x | 0.24x | 0.45x | 0.45x | 0.61x | -2.30x | 0.70x | 0.54x | 0.35x | 0.58x |
Interest Paid | 617K | 3.87M | 7.2M | 7.2M | 7.16M | 8.54M | 1.17M | 7K | 0 | 0 |
Taxes Paid | 566K | 216K | 48K | 48K | 36K | 0 | 21K | 4K | 0 | 0 |
PGEN Key Ratios
Precigen, Inc. (PGEN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -20.97% | -110.09% | -75.71% | -245.56% | -105.62% | 24.24% | -78.37% | -160.8% | -843.57% | -1768.51% |
Return on Invested Capital (ROIC) | -20.64% | -77.79% | -17.81% | -29.68% | -30.07% | -26.18% | -51.45% | -152.85% | -1553.78% | -150.53% |
Gross Margin | 72.82% | 60.59% | 83.2% | -40.04% | -276.24% | 76.44% | 1.7% | -8.71% | 37.05% | 75.63% |
Net Margin | -50.66% | -317.2% | -533.01% | -533.01% | -646.01% | 105.23% | -1540.63% | -3216.18% | -2588.21% | -646.99% |
Debt / Equity | 0.02x | 0.56x | 3.24x | 2.71x | 1.77x | 0.41x | 0.06x | 0.14x | 0.24x | 4.86x |
Interest Coverage | -211.27x | -45.42x | -4.74x | -4.65x | -4.87x | -10.80x | -204.90x | -21337.00x | -27.57x | -13.29x |
FCF Conversion | 0.89x | 0.24x | 0.45x | 0.45x | 0.61x | -2.30x | 0.70x | 0.54x | 0.35x | 0.58x |
Revenue Growth | 20.98% | -30.48% | -80.08% | 0% | -55.4% | 88.61% | -76.87% | -36.95% | 146.73% | 652.08% |
Related:PGEN Dividend History·PGEN Revenue History·PGEN Price History·PGEN P/E History·PGEN Financial Ratios·PGEN Institutional Holders
PGEN SEC Filings & Documents
Precigen, Inc. (PGEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
PGEN Frequently Asked Questions
Precigen, Inc. (PGEN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Precigen, Inc. (PGEN) reported $31.6M in revenue for fiscal year 2025. This represents a 294% increase from $8.0M in 2011.
Precigen, Inc. (PGEN) grew revenue by 146.7% over the past year. This is strong growth.
Precigen, Inc. (PGEN) reported a net loss of $204.4M for fiscal year 2025.
Dividend & Returns
Precigen, Inc. (PGEN) has a return on equity (ROE) of -843.6%. Negative ROE indicates the company is unprofitable.
Precigen, Inc. (PGEN) had negative free cash flow of $117.6M in fiscal year 2025, likely due to heavy capital investments.